


The background of the slide is a composite image. The bottom half shows a dark, multi-lane highway at night, viewed from a low angle looking down the road. The road is flanked by concrete barriers. In the distance, a city skyline is visible with numerous skyscrapers illuminated by lights. The top half of the image is a dark, starry sky. The word 'exozymes' is written in a red, sans-serif font across the top, with a red 'X' over the 'o'.

exozymes

The Next Generation of Biomufacturing

Michael Heltzen, CEO

eXoZymes' Safe Harbor

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this presentation regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

exoZymes' vision

Solving a generational problem

A lack of **sustainable access to chemicals**, which form the basis of modern life

enzymes × AI = exozymes

Resources via conventional methods

An oil drilling rig stands in a dark, desolate landscape under a night sky. The rig is illuminated by its own lights, and a small yellow vehicle is visible nearby.

Plant-derived
chemicals

A large industrial facility with multiple tall smokestacks is shown against a bright orange and yellow sunset sky. Thick white smoke is being emitted from one of the stacks.

Petroleum-based
chemicals

A close-up view of a microscope's objective lens positioned over a petri dish. Inside the dish, a small green plant seedling is growing out of dark soil.

Cell-based
synthetic biology

Problems with conventional methods



Plant-derived
chemicals

**Depleting natural
resources**



Petroleum-based
chemicals

**Polluting
and toxic**





Cell-based
synthetic biology

**Rarely makes it to
commercial scale**

Old SynBio paradigm: How cells makes chemicals

Sugar/Feedstock

Cell



Top reasons why SynBio/cells/fermentation is not ideal

1

Cells are, by evolution, designed to only do things that help the cell survive, grow, and replicate. They do not want to **produce chemicals** they do not need.

2

The cells often get sick or die from the **toxic** chemicals or the intermediates. Resulting in scaling problems and low titer results.

3


Most SynBio projects commercially die as the **isolation cost** to get the pure chemical, out of the cell slurry, is higher than the value of the chemical itself.




How are **exozymes** different to **synthetic biology**?

Old SynBio paradigm: How cells makes chemicals


Sugar/Feedstock



Cell



Why not just liberate the
Enzymatic Pathway from the cell?



Former belief system:
Enzyme Pathways does not
function outside of cells...

Cell-based enzymes vs **exozyme** biosolutions

cell-based synbio

Sugar/Feedstock



exozyme biosolutions

= exozymes (AI-optimized enzymes)
+ production pathways helper modules

Biomass/Sugar/
Feedstock



Cell-free Exozyme Pathway
& Support Modules

Chemistry
Product

- Engineering-level control
- Efficient use of feedstock
- High titer/yield
- Works and Scales like Chemistry

Enabling chemical and drug companies to turn natural resources into valuable chemicals **sustainably and affordably, including new kinds of chemistry**

enzymes × AI = exozymes


The background of the slide is a dark, high-contrast aerial photograph of a city skyline at night. The city lights are visible, and the overall tone is dark and moody.


enzymes × AI* = exozymes

- * Proprietary enzyme knowledge and technology – both wet-lab and dry-lab.
 - e.g. one of our secret sauces is how we generate enzyme training data.



The market leader of **cell-free** exozymes biomanufacturing



An aerial night photograph of a city, likely Los Angeles, showing a dense urban landscape with numerous buildings and a prominent highway in the foreground with light trails from traffic. The image is dark, with city lights providing the primary illumination.

cell-based SynBio was the last generation

exozymes is the next gen of biomanufacturing.



exoZymes

exozymes.com/exoz

Nutraceuticals with a pharmaceutical potential



An **exoZymes** biosolution for **NCT**

www.NCTx.one



An exozyme biosolution for
N-trans-Caffeoyltyramine – aka **NCT**



A Nutraceutical with Pharmaceutical Potential



A potent HNF4 α agonist, and candidate for fatty liver disease and gut health

www.NCTx.one



CAS: 103188-48-3
Purity: >98%

When **NCT** meets the HNF4a drug receptor it becomes a **potent agonist**



Agonist: A small molecule that, upon binding to a receptor, activates it and produces a biological response.

The **leading** pre-clinical model **experts** in the world, **say**...



► Cell Death Dis. 2021 Jun 11;12(6):603. doi: [10.1038/s41419-021-03862-x](https://doi.org/10.1038/s41419-021-03862-x)

Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist



► PLoS One. 2022 Apr 6;17(4):e0266066. doi: [10.1371/journal.pone.0266066](https://doi.org/10.1371/journal.pone.0266066)

A potent HNF4α agonist reveals that HNF4α controls genes important in inflammatory bowel disease and Paneth cells

“NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD (fatty liver disease) therapeutic.”

“These (studies and) data suggest that HNF4a could be a therapeutic target for Inflammatory bowel disease and that the (NCT) agonists that we have identified could be candidate therapeutics.”

What is Non-Alcoholic Fatty Liver Disease (NAFLD)?

Size of problem

- Globally impacts over 30% of adults and growing fast
- Closely linked to obesity, gut health, maybe diabetes
- Very few good medical options
- A huge problem for the individual and society



exoZymes

NCT - The first of many natural products and new-to-nature
analogs that can **now** be **biomanufactured**



As well as **extraordinary** business opportunities

As well as extraordinary business opportunities



Customer(s) via grants:

DoD & DoE

Isobutanol used as Sustainable Aviation Fuel (SAF)

- A liquid fuel already used in commercial aviation, which reduces CO2 emissions by up to 80%
- A politically mandated hyper-growth market in both US and EU

Aviation Fuel Market: **\$793B**

\$220B

2022

2030

Source: The International Air Transport Association (IATA.org) and Acumen Research and Consulting

Approx **\$14MM** in **US Gov grants** enabling the development of our cell free platform technology



Cannabinoids
Phase I SBIR \$150k

Cannabinoids
Phase II SBIR \$2MM

Methylation
Phase I SBIR \$245k

Cell-Free Tools
BioClick Chemistry \$300k



Cofactors
Phase II SBIR \$2.3MM

Isobutanol
BETO \$2.1MM
\$3.7MM

Alcohols
ARPAe \$1.6MM

Proteins
ARPAe SBIR \$500K



Proteins
TCF \$150k

Cell-Free
Subcontract \$50k



Protein Scaleup
BioMade \$805k

Background

Location: Pasadena, CA. 30 full-time, and a very large support system.

2019: UCLA spin-out, “Big Idea” status = MDB Capital backed.

2020/22: POC projects and technology platform development.

2023: AI/ML and state-of-the-art enzyme engineering capabilities.

2024: Commercial CEO, focus strategy, rebranding and Nasdaq IPO

2025: Applications and traction with “powered by exozymes” (NCT etc.)



Damien
Perriman
CCO

Paul
Opgenorth, PhD
VP of Development

Tyler
Korman, PhD
VP of Research

Michael
Heltzen
CEO

Fouad
Nawaz
VP of Finance

Zachary
Karl, PhD
VP of Business Development

Lasse H.
Görlitz
VP of Comms

exoZymes Inc.

a platform-of-platforms company

short term: kick-starting tech use via spin-outs and JVs,

longer term: mostly sell and license exozymes technology




The future is **bright**



If you want to learn more as an investor

www.exozymes.com/exoz



Thank you for your attention and participation!

Questions

Financials

Please see **[exozymes.com/sec-filings](https://www.exozymes.com/sec-filings)** for details

Recognized leader of cell-free biomanufacturing in peer-reviewed scientific journals



3x published




Cover story



4x published

eXoZymes R&D de-risking and speed-up process





Business model leverages **IP** for proprietary processes,
key enzymes, and novel chemicals

10+ patents and substantial **trade secrets** protecting

Patents &
trade secrets


Novel cell-free
biomanufacturing

**Advanced AI &
R&D platform**


Novel Enzymes
& exozymes

Novel & rare
chemicals

Focus on opportunities and markets that create value for our shareholders



Partnership deal funnel optimization



Key Considerations

- Discernment in deal selection
- Balanced funnel dynamics
- Continuous replenishment
- Efficient transition and progression
- Quality over quantity
- Strategic abandonment


Next generation **biomanufacturing** for **drug discovery** and development

- Enables new and better drugs **otherwise impossible to make**
- Allows for the biochemical engineering and mass production of a new generation of complex drug molecules, **by overcoming the limitations of cellular metabolism** and first-generation synthetic biology
- Allows for chemical engineering level control (biocatalysis) at never seen before levels by using **the best of biology and chemistry simultaneously**

Isobutanol used as Sustainable Aviation Fuel (SAF)

- A liquid fuel already used in commercial aviation, which reduces CO2 emissions by up to 80%
- Comprises less than 0.1% of aviation fuels, but all airlines are looking for suppliers
- Healthy premiums/subsidies paid for SAF over fossil fuels
- A politically mandated hyper-growth market in both US and EU
- 70% of jet fuels at EU airports mandated to be SAF by 2050

Total Addressable Market (US)



Source: The International Air Transport Association (IATA.org) and Acumen Research and Consulting

Business model with **assymetric upside** potential

Limited Downside

- Foundational patents
- Capital light
- Government grants & partners cover cost

Unlimited Upside

- Unlimited markets
- Multiple revenue streams :
 - License fees
 - Royalties (1%—8%)
 - Critical enzyme sales

High Impact on NPV

- Ability to disrupt multiple, multi-billion-dollar markets
- Value creation potential significant without the risk profile and cost of competing directly
- Potential to generate significant investor returns relative to capital requirement

By partnering, instead of trying to compete,
we have **multiple shots on goal in multiple markets**